t
Sareum Holdings PLC announced that Dr Stephen Parker, Non-Executive Chairman, purchased 12,500 ordinary shares at an average price of 80 pence per share on 5 September 2023. Following this transaction, Dr Parker holds direct and indirect interests in an aggregate of 116,160 Ordinary Shares, representing approximately 0.16% of the Company's currently issued share capital.
| Date | 6 Sept 2023 |
| Time | 07:00:06 |
| Category | Director/PDMR dealings |
| ID | 4654L |
Sareum Holdings PLC
("Sareum" or the "Company")
Director's Dealing
Cambridge, UK, 05 September 2023 - Sareum Holdings plc (AIM: SAR), a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, announces that Dr Stephen Parker, Non-Executive Chairman, purchased 12,500 ordinary shares of 0.0125 pence each in the Company ("Ordinary Shares") at an average price of 80 pence per share on 5 September 2023.
In addition, persons connected with Dr Parker are interested in a further 25,680 Ordinary Shares in the Company, over which Ordinary Shares Dr Parker has voting rights discretion.
Therefore, following the transaction, Dr Parker has direct and indirect interests in an aggregate 116,160 Ordinary Shares in the Company, representing approximately 0.16 per cent. of the Company's currently issued share capital.
The notification below, which has been made in accordance with the requirements of the Market Abuse Regulation, provides further details.
PDMR Notification Form:
|
1 |
Details of the person discharging managerial responsibilities/person closely associated
|
|||||
|
a) |
Name |
Stephen Parker |
||||
|
2 |
Reason for the notification |
|||||
|
a) |
Position/status |
Non-Executive Chairman |
||||
|
b) |
Initial notification/amendment |
Initial notification |
||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
Sareum Holdings plc |
||||
|
b) |
LEI |
213800PKERN2DY8FFM72 |
||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument |
Ordinary shares of 0.0125 pence each in the share capital of Sareum Holdings plc |
||||
|
|
|
|
||||
|
|
Identification code |
GB00B02RFS12 |
||||
|
|
|
|
||||
|
b) |
Nature of the transaction |
Purchase of shares |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
|
£0.80 |
12,500 |
|
|
|
|
|
|
|
|
|
|
|
d) |
Aggregated information |
|
|
|||
|
|
|
|
|
|||
|
|
- Aggregated volume |
12,500 ordinary shares |
|
|||
|
|
|
|
|
|||
|
|
- Weighted Average Price |
80 pence per share |
|
|||
|
|
|
|
|
|||
|
e) |
Date of the transaction |
5 September 2023 |
|
|||
|
f) |
Place of the transaction |
London Stock Exchange (AIM) |
|
|||
The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014, which is part of UK law by virtue of the European Union (Withdrawal) Act 2018.
- Ends -
For further information, please contact:
|
Sareum Holdings plc Tim Mitchell, CEO Lauren Williams, Head of Investor Relations |
01223 497700
|
|
Strand Hanson Limited (Nominated Adviser) James Dance / James Bellman
|
020 7409 3494 |
|
Peel Hunt LLP (Joint Corporate Broker) James Steel / Patrick Birkholm
|
020 7418 8900 |
|
Hybridan LLP (Joint Corporate Broker) Claire Noyce
|
020 3764 2341 |
|
Consilium Strategic Communications (Financial PR) Jessica Hodgson / Davide Salvi / Stella Lempidaki
|
020 3709 5700 |
About Sareum
Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.
The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases and has entered Phase 1a/b clinical development with an initial focus on psoriasis.
Sareum has an economic interest in SRA737, a clinical-stage Chk1 inhibitor which it originally developed in collaboration with several Cancer Research UK-related organisations. SRA737 has shown promising safety and efficacy in two Phase 1/2 clinical trials.
Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.
Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com